Karolinska Development: Enrollment completed in Modus phase II trial
Research Note
2019-01-07
13:53
Modus Therapeutics announced today that the enrollment has been completed in the ongoing trial with sevuparin in Sickle Cell Disease.
AN
AH
Arvid Necander
Anders Hedlund
Disclosures and disclaimers